This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Authored By: Lucia Rose, PharmD, BCIDP. Article Posted 1 December 2022. It was the fall of 2009; I was a proud PGY-1 resident at UMass Medical Center rounding with a large team in the ICU.
Lecanemab is an investigational anti-amyloid beta antibody to treat mild cognitive impairment due to Alzheimer’s disease. It is currently under review by the FDA and a decision is expected by January 6, 2023.
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.
Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.
Gilead Sciences won a key round in its battle with the U.S. government over allegations that the Centers for Disease Control and Prevention breached several contracts and “secretly” obtained patents stemming from research that led to the groundbreaking Truvada pill for preventing HIV. As part of a broader fight with the agency over research and resulting patent rights to the medication, the company had filed a lawsuit in 2020 alleging the CDC violated the terms of a 15-year-old col
The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above. A live biotherapeutic, Rebyota is intended for usage following the completion of antibiotic treatment. Rebyota’s safety and efficacy were analysed in the largest trial programme in the microbiome-based therapeutics field, including five trials enrolling over 1,000 subjects.
Amgen released detailed data on Thursday suggesting an early-stage drug can induce significant weight loss in patients with obesity, with less frequent dosing than current treatments but a safety profile that remains unclear. The results for the molecule, codenamed AMG133, throw Amgen in a long-gestating race with other major drugmakers that burst into the popular press this year.
A recent essay in Health Affairs, a prominent health care journal, proposed a useful-sounding idea: The government should create a new federal designation for “essential hospitals” — hospitals that, according to their own metrics, serve a safety-net role but aren’t currently recognized as such. But it isn’t useful at all.
Results from a Phase II/III study , published in The Lancet , showed a single, oral dose of acoziborole was up to 95 percent successful in treating sleeping sickness (human African trypanosomiasis). About the Phase II/III study. Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. 208 patients were recruited at 10 hospitals in the Democratic Republic of the Congo (DRC) and
At a time when many Americans are clamoring for more transparency into prescription drug pricing, one key provider of that data is making it harder to access the information. A new venture called Merative — which was formed recently from the ashes of IBM’s Watson Health division — has decided it will no longer provide the media with pricing changes for specific medicines.
According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The analytics company asserted that despite no mRNA non-vaccine therapeutics currently being in the market, this statistic is derived from the combined revenue expected from Moderna, Ultragenyx, Omega Therapeutics, and BioNTech’s investigational therapies for cancer and rare genetic diseases, all in
The pharmaceutical industry is highly regulated, and for a good reason. Laws and regulations are set to ensure that consumers and patients can access safe and effective medications, medical devices, and other products. In order to test, market, and release drugs onto the market, pharmaceutical companies must abide by government regulations and oversight processes. .
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content